NasdaqHealth CareHealth Care EquipmentS&P 500Nasdaq-100
$82.38
-1.37 (-1.64%)
Close of Nov 06, 2026 · end-of-day data
GEHC 8-K filings in 2025
Every material Form 8-K GE HealthCare filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On December 15, 2025, GE HealthCare issued $600 million of 4.150% senior notes due 2028 and $650 million of 4.950% senior notes due 2035. On December 12, 2025, it also agreed to a three-year, $750 million unsecured term loan with JPMorgan Chase Bank, N.A. as administrative agent. The company says it will use these proceeds and cash on hand to pay the purchase price for its previously announced acquisition of Intelerad Medical Systems, which adds new debt that shareholders should weigh against the deal.
$600 million 4.150% senior notes due December 15, 2028, and $650 million 4.950% senior notes due December 15, 2035, issued December 15, 2025
$750 million three-year unsecured term loan under a credit agreement dated December 12, 2025, with JPMorgan Chase Bank, N.A. as administrative agent; the loan will be made in a single borrowing on a future date
Proceeds, the term loan and cash on hand are intended to pay the purchase price for the Intelerad Medical Systems acquisition
The term loan agreement includes covenants limiting liens, fundamental change transactions, leverage and subsidiary debt, plus a change-of-control event of default
GE HealthCare reported third quarter 2025 revenue of $5.1 billion, up 6% from a year earlier, but adjusted earnings per share fell to $1.07 from $1.14 as tariffs weighed on profit. The company raised the lower end of its full-year 2025 adjusted EPS guidance to $4.51 from $4.43 and reaffirmed its other targets.
Revenue of $5.1 billion rose 6% reported and 4% organic year over year; total company orders grew 6% organically.
Net income attributable to GE HealthCare was $446 million versus $470 million; diluted EPS was $0.98 versus $1.02.
Adjusted EPS was $1.07 versus $1.14; the company said tariffs hurt margin and EPS, and would have exceeded prior year without them.
Full-year 2025 adjusted EPS guidance is $4.51 to $4.63, including about $0.45 of tariff impact; free cash flow for the quarter was $483 million versus $651 million.
GE HealthCare reported second quarter 2025 revenue of $5.0 billion, up 3% from a year earlier, and net income attributable to the company of $486 million versus $428 million. It raised its full-year 2025 adjusted EPS guidance to $4.43 to $4.63 from $3.90 to $4.10, and its free cash flow guidance to at least $1.4 billion from at least $1.2 billion. Adjusted EBIT margin fell to 14.6% from 15.3%, which the company attributed mainly to tariffs.
Q2 2025 revenue was $5.0 billion, up 3% reported and 2% organic year over year.
Diluted EPS was $1.06 versus $0.93; adjusted EPS was $1.06 versus $1.00.
2025 adjusted EPS guidance raised to $4.43 to $4.63 from $3.90 to $4.10, including about $0.45 of tariff impact.
Adjusted EBIT margin was 14.6% versus 15.3%, down 80 bps, impacted by tariffs.
GE HealthCare Technologies disclosed that director Lloyd W. Howell, Jr. resigned from its Board of Directors, effective immediately, with notice given on July 23, 2025. The company said the resignation was not due to any disagreement over its operations, policies, or practices.
Lloyd W. Howell, Jr. notified the company of his resignation on July 23, 2025
Resignation from the Board is effective immediately
Company states no disagreement on operations, policies, or practices led to the departure
GE HealthCare reported first quarter 2025 revenue of $4.8 billion, up 3%, and diluted EPS of $1.23 versus $0.81 a year earlier. The company also cut its full-year 2025 guidance, including adjusted EPS of $3.90 to $4.10 versus prior guidance of $4.61 to $4.75, and said the outlook includes about $0.85 of tariff impact. The Board also authorized a $1 billion share repurchase program with no expiration date.
Q1 2025 revenue $4.8 billion, up 3% reported and 4% organic; diluted EPS $1.23 versus $0.81; adjusted EPS $1.01 versus $0.90
2025 adjusted EPS guidance lowered to $3.90-$4.10 from $4.61-$4.75, including about $0.85 of tariff impact
Free cash flow guidance lowered to at least $1.2 billion from at least $1.75 billion; Q1 free cash flow was $98 million versus $274 million
Board authorized up to $1 billion in share repurchases with no expiration date
On March 27, 2025, GE HealthCare entered into two new unsecured revolving credit facilities with JPMorgan Chase Bank as administrative agent, totaling $3.5 billion in committed amounts. The new facilities replaced two earlier credit agreements, which were terminated without penalty on the same date. The filing describes a refinancing of existing credit capacity rather than new borrowing, and it discloses no drawn amounts.
New $3.0 billion senior unsecured revolving credit facility matures March 27, 2030
New $0.5 billion 364-day revolving credit facility matures March 26, 2026
Replaces a $1.0 billion facility from December 11, 2024 (Citibank) and a $2.5 billion facility from November 4, 2022 (Citibank), both terminated March 27, 2025
GE HealthCare reported fourth-quarter 2024 revenue of $5.3 billion, up 2% year over year, and diluted EPS of $1.57 versus $0.88 a year earlier. For full-year 2024, revenue was $19.7 billion, up 1%, and adjusted EPS was $4.49 versus $3.93. The company also introduced 2025 guidance calling for adjusted EPS of $4.61 to $4.75, which it says represents 3% to 6% growth.
Q4 2024 revenue was $5.3 billion, up 2%; net income attributable to GE HealthCare was $720 million versus $403 million
Q4 2024 adjusted EPS was $1.45 versus $1.18; full-year 2024 adjusted EPS was $4.49 versus $3.93
2025 guidance: organic revenue growth of 2% to 3%, adjusted EBIT margin of 16.7% to 16.8%, and free cash flow of at least $1.75 billion
Full-year 2024 free cash flow was $1.6 billion, down $161 million year over year
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every GE HealthCare filing is on SEC EDGAR ↗. 8-K briefs of other companies →